Departments of Chemistry and Neuroscience, The Scripps Research Institute , 130 Scripps Way, Jupiter, Florida 33458, United States.
Chem Rev. 2018 Feb 28;118(4):1599-1663. doi: 10.1021/acs.chemrev.7b00504. Epub 2018 Jan 11.
Rapid progress in genome sequencing technology has put us firmly into a postgenomic era. A key challenge in biomedical research is harnessing genome sequence to fulfill the promise of personalized medicine. This Review describes how genome sequencing has enabled the identification of disease-causing biomolecules and how these data have been converted into chemical probes of function, preclinical lead modalities, and ultimately U.S. Food and Drug Administration (FDA)-approved drugs. In particular, we focus on the use of oligonucleotide-based modalities to target disease-causing RNAs; small molecules that target DNA, RNA, or protein; the rational repurposing of known therapeutic modalities; and the advantages of pharmacogenetics. Lastly, we discuss the remaining challenges and opportunities in the direct utilization of genome sequence to enable design of medicines.
基因组测序技术的快速发展使我们稳稳地进入了后基因组时代。生物医学研究的一个关键挑战是利用基因组序列来实现个性化医疗的承诺。这篇综述描述了基因组测序如何使我们能够识别致病生物分子,以及这些数据如何转化为功能化学探针、临床前先导模式,最终成为美国食品和药物管理局 (FDA) 批准的药物。特别是,我们重点关注基于寡核苷酸的模式来靶向致病 RNA;靶向 DNA、RNA 或蛋白质的小分子;合理重新利用已知的治疗模式;以及药物遗传学的优势。最后,我们讨论了直接利用基因组序列来设计药物的剩余挑战和机遇。